Insights

Gathering insights about SRP…

Similar companies to SRP

SRP Tech Stack

SRP uses 8 technology products and services including Auth0, Element UI, jQuery UI, and more. Explore SRP's tech stack below.

Auth0
Identity Verification
Element UI
Javascript Frameworks
jQuery UI
Javascript Libraries
Moment.js
Javascript Libraries
Twitter typeahead.js
Javascript Libraries
Pardot
Marketing
HSTS
Security
HTTP/3
Web & Portal Technology

Media & News

Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS
Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 10.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,250 shares of the biotechnology company's stock after purchasing an additional
Nov 27, 2025 | www.defenseworld.net
Envestnet Asset Management Inc. Decreases Stake in Sarepta Therapeutics, Inc. $SRPT
Envestnet Asset Management Inc. lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 33.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,998 shares of the biotechnology company's stock after selling 12,361 shares during the quarter. Envestnet
Nov 27, 2025 | www.defenseworld.net
Sarepta's Stock Rises on Positive Updates on DM1 Therapy
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
Nov 25, 2025 | www.zacks.com
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.'s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).
Nov 25, 2025 | www.benzinga.com
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved dosing in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with ELEVIDYS (delandistrogene moxeparvovec-rokl) for non-ambulant individuals with Duchenne muscular dystrophy. Data from Coh.
Nov 25, 2025 | www.businesswire.com
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly ARO-DM1), an investigational small interfering RNA (siRNA) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Cohorts 1 (1.5 mg/kg) and 2 (3 mg/kg) of the study are complete, and cohort 3 (4.5 mg/kg) is fully enrolled and ongoing. Following.
Nov 24, 2025 | www.businesswire.com
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.
Nov 24, 2025 | www.businesswire.com

SRP's Email Address Formats

SRP uses at least 1 format(s):

SRP Email Formats	Example	Percentage
Last@structuredretailproducts.com	Doe@structuredretailproducts.com	41%
First@structuredretailproducts.com	John@structuredretailproducts.com	13%
First.Last@structuredretailproducts.com	John.Doe@structuredretailproducts.com	5%
Last@structuredretailproducts.com	Doe@structuredretailproducts.com	41%

Frequently Asked Questions

Where is SRP's headquarters located?

SRP's main headquarters is located at 4 Bouverie Street, London, EC4 8AX, GB. The company has employees across 4 continents, including EuropeAsiaNorth America.

What is SRP's stock symbol?

SRP is a publicly traded company; the company's stock symbol is SRPT.

What is SRP's official website and social media links?

SRP's official website is structuredretailproducts.com and has social profiles on LinkedIn.

What is SRP's NAICS code?

SRP's NAICS code is 52 - Finance and Insurance.

How many employees does SRP have currently?

As of October 2025, SRP has approximately 102 employees across 4 continents, including EuropeAsiaNorth America. Key team members include Head Of Data Apac: V. K.Company Owner: I. S.Senior Operations Manager: V. C.. Explore SRP's employee directory with LeadIQ.

What industry does SRP belong to?

SRP operates in the Financial Services industry.

What technology does SRP use?

SRP's tech stack includes Auth0Element UIjQuery UIMoment.jsTwitter typeahead.jsPardotHSTSHTTP/3.

What is SRP's email format?

SRP's email format typically follows the pattern of Last@structuredretailproducts.com. Find more SRP email formats with LeadIQ.

When was SRP founded?

SRP was founded in 2003.

SRP

Q: What is SRP's official website and social media links?

SRP's official website is structuredretailproducts.com. SRP has social profiles on LinkedIn.

Q: How many employees does SRP have currently?

SRP has approximately 102 employees.

Q: What technology does SRP use?

SRP's tech stack includes jQuery UI, JSON-LD, HSTS, DoubleClick for Publishers (DFP), Wistia.

Financial ServicesUnited Kingdom51-200 Employees

Connect to SRP – the most comprehensive, trusted source of structured products data and market intelligence. 

At the heart of the global investment community, we draw on deep expertise and broad coverage to deliver a rich mix of data solutions, insights, conferences and awards that celebrate the best in the industry. 

The choice of leading investment banks, hedge funds, product issuers and distributors, exchanges and asset managers, we provide everything you need to understand and stay ahead of the market. Welcome to connected intelligence.

SRP is a part of Derivia Intelligence, the world’s leading provider of critical data and market intelligence for derivatives and complex financial instruments.